Eudaimonia Partners’s Alterity Therapeutics ATHE Stock Holding History

Eudaimonia Partners’s Portfolio ATHE Stock Details ATHE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-2,500	Closed	-$30K	–	804
2020 Q2	$30K	Buy	+2,500	New	+$15.9K	0.01%	621
2020 Q1	–	Sell	-5,000	Closed	-$39K	–	671
2019 Q4	$39K	Buy	+5,000	New	+$50.3K	0.02%	539

Other funds holding ATHE

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GWM

Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

SWM

Sugarloaf Wealth Management Duluth, Georgia $529M AUM 14.14% 1-Year Est. Return

APA

American Portfolios Advisors Holbrook, New York $2.36B AUM 14.59% 1-Year Est. Return

Eudaimonia Partners's ATHE Position: Q3 2020 in Review

Eudaimonia Partners sold out of Alterity Therapeutics (ATHE) in Q3 2020, closing a stake of 2,500 shares — an estimated $30K sold.

Eudaimonia Partners first reported a position in ATHE in Q4 2019 and held it in 2 quarters. The position peaked at $39K in Q4 2019. 10 funds tracked by Wall St. Rank hold ATHE as of Q3 2020.

Eudaimonia Partners reported no remaining Alterity Therapeutics position as of Q3 2020 after selling out during the quarter.
Eudaimonia Partners sold 2,500 Alterity Therapeutics shares in Q3 2020, an estimated $30K.
Eudaimonia Partners first reported a position in Alterity Therapeutics in Q4 2019 and held it in 2 quarters.
Eudaimonia Partners's Alterity Therapeutics position peaked at $39K in Q4 2019.
10 funds tracked by Wall St. Rank held Alterity Therapeutics as of Q3 2020.

Based on Eudaimonia Partners's 13F filing for Q3 2020, filed 16 Nov 2020.